



FINANCIAL TEAR SHEET

CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life-improving drugs. For more than 30 years, we've been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in over 100 countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug development process.

We help change people's lives for the better every single day. It's what we are passionate about.

STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$81.11
Change (%)	▲ 0.22 (0.27%)
Volume	72,336
52 Week Low	\$69.70
Market Cap	\$5,197,222,285
Rolling EPS	1.73
PE Ratio	46.8808
Shares Outstanding	64,076,221
Data as of 05/25/18 4:00 p.m. ET	



NEWS & EVENTS

Date	Title
------	-------

There are currently no events scheduled.

05/24/18	PRA Named International Clinical Research Company of the Year
05/03/18	PRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America's Best Large Employers List
04/25/18	PRA Health Sciences Announces Retirement of Chief Financial Officer and Promotion of Michael Bonello to CFO

SEC FILINGS

Filing Date	Form
05/01/18	3
05/01/18	8-K
04/26/18	10-Q
04/25/18	8-K

BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)